Role of 99mTc-pyrophosphate myocardial scintigraphy in assessing the efficiency of tafamidis therapy: a case series

Introduction . In recent years, the detection rate of transthyretin amyloid cardiomyopathy has been rapidly increasing. The only drug registered as a pathogenetic therapy in Russia is tafamidis. To date, there is no single protocol for assessing disease progression, and the role of scintigraphy with phosphate complexes is not reflected in current documents due to the lack of evidence. Brief description . The article presents a case series including patients who received tafamidis therapy for at least 12 months. During therapy, there were no signs of disease progression, and in some cases, according to myocardial scintigraphy with phosphate complexes, a decrease in radiopharmaceutical uptake was noted. Discussion . The role of myocardial scintigraphy with phosphate complexes for monitoring the effectiveness of tafamidis therapy was discussed.